Rabies antibody response after two intradermal pre-exposure prophylaxis immunizations: An observational cohort study

Abstract

Implementation of this two-dose schedule will protect more people against Rabies. Travelers and military personnel under time constraints, who otherwise would remain unvaccinated, can be considered adequately protected after this two-dose schedule. For populations in endemic areas, local application of a two-dose schedule could provide an opportunity to vaccinate more people with less vaccine. Given the paucity of published data, this study adds relevant evidence in support of the new policy (2017) of WHO, concerning a two-dose, seven-day schedule is approved for all healthy individuals.

Purified Vero Cell Rabies Vaccine (PVRV, Verorab®): A Systematic Review of Intradermal Use Between 1985 and 2019

“…There were 11 citations identified that reported immunogenicity data following ID PVRV for PrEP [16,[20][21][22][23][24][25][26][27][28][29]; of these, 6 were undertaken in Thailand [20,23,25,[28][29][30]. The other studies were undertaken in Vietnam [24,27] (both these Vietnamese studies reported data on the same cohort of children), Brazil [22], and The Netherlands [16,21].…”

“…Seroconversion rates from day 14 to 56 after the first vaccination and at 1 year across the studies identified were 90-100% and 20-96%, respectively [16,[21][22][23]25,[27][28][29]. The RVNA GMTs reported across the studies irrespective of PrEP regimen (n = 926), including following booster vaccination after one year, are summarized in Figure 2 [16,[20][21][22][23][24][25][26][27][28][29]. The GMT range across studies from day 14 to 56 after the first vaccination was 1.90-14.35 IU/mL decreasing to ≤1.9 IU/mL at 1 year [16,[20][21][22][23]26,29].…”

“…There were 11 citations identified that reported immunogenicity data following ID PVRV for PrEP [16,[20][21][22][23][24][25][26][27][28][29]; of these, 6 were undertaken in Thailand [20,23,25,[28][29][30]. The other studies were undertaken in Vietnam [24,27] (both these Vietnamese studies reported data on the same cohort of children), Brazil [22], and The Netherlands [16,21]. The study populations included: children aged < 1 year [24,27]; children aged 12-16 months [29]; children aged 5-12 years [23]; children and adults [25] or where age was not specified (assumed to be children and adults) [26]; and adults [16,[20][21][22]28].…”

“…The other studies were undertaken in Vietnam [24,27] (both these Vietnamese studies reported data on the same cohort of children), Brazil [22], and The Netherlands [16,21]. The study populations included: children aged < 1 year [24,27]; children aged 12-16 months [29]; children aged 5-12 years [23]; children and adults [25] or where age was not specified (assumed to be children and adults) [26]; and adults [16,[20][21][22]28]. Details of the studies and immunogenicity data identified are summarized in Table S1 (Supplementary Materials).…”

“…Seroconversion rates from day 14 to 56 after the first vaccination and at 1 year across the studies identified were 90-100% and 20-96%, respectively [16,[21][22][23]25,[27][28][29]. The RVNA GMTs reported across the studies irrespective of PrEP regimen (n = 926), including following booster vaccination after one year, are summarized in Figure 2 [16,20−29].…”